These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 29433529)

  • 1. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer.
    Wu SG; He ZY; Zhou J; Sun JY; Li FY; Lin Q; Guo L; Lin HX
    Breast; 2014 Feb; 23(1):88-93. PubMed ID: 24291374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy.
    Fujimoto Y; Higuchi T; Nishimukai A; Miyagawa Y; Kira A; Ozawa H; Bun A; Imamura M; Miyoshi Y
    J Surg Oncol; 2018 Jul; 118(1):228-237. PubMed ID: 29936704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preoperative serum CA15.3 and CEA levels and clinical-biological parameters in breast tumors].
    Ruibal A; Garrido Pumar M; Arias JI
    Rev Esp Med Nucl; 2006; 25(3):180-3. PubMed ID: 16762272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.
    Nam SE; Lim W; Jeong J; Lee S; Choi J; Park H; Jung YS; Jung SP; Bae SY
    Breast Cancer Res Treat; 2019 Oct; 177(3):669-678. PubMed ID: 31312932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.
    Li J; Liu L; Feng Z; Wang X; Huang Y; Dai H; Zhang L; Song F; Wang D; Zhang P; Ma B; Li H; Zheng H; Song F; Chen K
    Breast Cancer; 2020 Jul; 27(4):621-630. PubMed ID: 32040723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer.
    Molina R; Auge JM; Farrus B; Zanón G; Pahisa J; Muñoz M; Torne A; Filella X; Escudero JM; Fernandez P; Velasco M
    Clin Chem; 2010 Jul; 56(7):1148-57. PubMed ID: 20472825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer.
    Zhao W; Li X; Wang W; Chen B; Wang L; Zhang N; Wang Z; Yang Q
    Dis Markers; 2021; 2021():5529106. PubMed ID: 34621407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
    Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
    Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
    Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
    Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
    Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
    Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
    Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
    Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients.
    Dai D; Chen B; Tang H; Wang B; Zhao Z; Xie X; Wei W
    PLoS One; 2016; 11(8):e0161902. PubMed ID: 27561099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.